Clinical trials: Differentiated Thyroid Carcinoma
Thyroid Neoplasm Follicular, Bone Metastases
Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases
Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone…
- Trial name
- NCT05466812
- Testing
- Sr-89
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid Cancer
Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer
Single intravenous administration of TAH-1005 is performed in patients with differentiated thyroid cancer (papillary cancer, follicular cancer) who cannot obtain therapeutic effect with standard treatment or who have difficulty…
- Trial name
- NCT05275946
- Testing
- Targeted alpha therapy
- Where
- Japan
- Volunteers
- 11 people
- Sponsor
- Osaka University
Thyroid Cancer, Cancer of the Thyroid
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).
- Trial name
- NCT07092514
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
DTC - Differentiated Thyroid Cancer
Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
The purpose of this study is to evaluate the efficacy of anlotinib in patients with locally advanced or metastatic differentiated thyroid cancer resistant to iodine therapy.
- Trial name
- NCT05007093
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Yansong Lin
Thyroid Cancer, Relapse
Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma
The purpose of the study is to evaluate the concordance between the 18F-PET/CT under thyrotropin stimulation and the diffusion-weighted Magnetic Resonance Imaging, in the detection of residual mass in 40 patients with partial…
- Trial name
- THYRIRMTEP (NCT02515084)
- Testing
- PET, MRI imaging
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Centre Henri Becquerel
Differentiated Thyroid Cancer
rhTSH for Radioactive Iodine Remnant Ablation in Differentiated Thyroid Cancer
This is a randomized, open, parallel controlled, multi-center clinical trial; 120 subjects were randomly assigned to the test group and the control group according to 3:1.
- Trial name
- NCT04447183
- Testing
- Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH), radioactive iodine
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Thyroid Cancer
Comparison of Quality of Life in Patients with Differentiated Thyroid Carcinoma Undergoing Different Surgery
The incidence of thyroid cancer has increased rapidly in recent years, especially in women. Early differentiated thyroid cancer has a good prognosis, and surgery is the main treatment.
- Trial name
- NCT06037174
- Testing
- minimally invasive procedure, Conventional Open Surgery
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Malignant Neoplasm of Thyroid Stage I, Malignant Neoplasm of Thyroid Stage II
Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer
Differentiated thyroid cancer is the most common neoplasm of endocrine system. After surgery and radioiodine treatment, thyroid stimulating hormone (TSH) suppression is the main goal which is achieved with levothyroxine…
- Trial name
- NCT01341886
- Testing
- Metformin
- Where
- Iran
- Volunteers
- 51 people
- Sponsor
- Mashhad University of Medical Sciences
Differentiated Thyroid Cancer (DTC)
The EMIRATES Study
This pilot study will take place in thyroid outpatient clinics. It will have two study arms running in consecutive order: first, a Control arm where standard care will take place without PDA-TC, then a Patient Decision Aid (PDA)…
- Trial name
- NCT06855680
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Malignant Neoplasm of Thyroid, Heart Diseases
Thyrotropin Over-suppression and Heart
The investigators evaluated the cardiac effects of Thyroid-stimulating hormone (TSH) over-suppression in women with differentiated thyroid cancer (DTC) frequently encountered during suppression therapy.
- Conditions
- Malignant Neoplasm of Thyroid, Heart Diseases, Thyrotoxicosis on Thyroxine Therapy
- Trial name
- NCT02645786
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Recombinant Human Thyroid Stimulating Hormone
Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer
Exogenous injection of recombinant human thyroid stimulating hormone (rhTSH) can elevate TSH in the short term (2 days) to meet the requirements of diagnostic 131I SPECT/CT whole-body scans.
- Trial name
- NCT06431620
- Testing
- Recombinant Human Thyroid Stimulating Hormone
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Differentiated Thyroid Cancer (DTC), Poorly Differentiated Thyroid Cancer
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Phase II, non-randomized, open-label study to determine the efficacy of cabozantinib as a firstline treatment for patients with differentiated thyroid cancer (DTC). Subjects will receive drug at a starting dose of 60mg PO QD.
- Trial name
- NCT02041260
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Thomas Jefferson University
Soft Tissue Sarcomas, Thyroid Cancer
11C-Acetate PET/CT Non-FDG-Avid Tumors
F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual tumor.
- Conditions
- Soft Tissue Sarcomas, Thyroid Cancer, Lung Cancer, Indolent Lymphoma
- Trial name
- NCT00687778
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Thyroid Cancer
UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
This is a Phase 2 Study of Everolimus and Lenvatinib in patients with metastatic differentiated thyroid cancer who have progressed on lenvatinib alone. Patient will have imaging, lab test and physical exams
- Trial name
- NCT03139747
- Testing
- Lenvatinib, Everolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Jefferson University
Differentiated Thyroid Cancer
Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
Background: BRAFV600E is the most frequent oncogene in differentiated thyroid cancer (DTC) occurring in about 50% of cases. Clinical trials with tyrosine kinase inhibitors (TKI) with specific activity against BRAF in metastatic…
- Trial name
- NCT01700699
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Salerno
Thyroid Cancer
Psycho-oncological Intervention Through Counselling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine
Diagnosis and treatment of differentiated thyroid carcinomas cause anxiety and depression. Additionally, these patients suffer hormonal alterations, associated with psychological symptoms (changes in mood, emotional instability…
- Trial name
- COUNTHY (NCT05054634)
- Testing
- Psycho-oncological Intervention Based on Counselling (PIBC)
- Where
- Spain
- Volunteers
- 75 people
- Sponsor
- Quironsalud
Differentiated Thyroid Cancer
A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with Donafenib 0.3g Bid by continuous oral…
- Trial name
- DTC (NCT03602495)
- Testing
- Donafenib
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Thyroid Cancer
Study of Apatinib in Patients With Differentiated Thyroid Cancer
The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer
- Trial name
- NCT02731352
- Testing
- Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid Neoplasm
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Background: Patients who have advanced thyroid cancer have a low long-term survival rate. These types of thyroid cancer do not respond well to conventional surgery or radiation, or to specific thyroid cancer treatments such as…
- Trial name
- NCT01182285
- Testing
- Valproic Acid, Liothyronine Sodium
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
- Trial name
- NCT00625846
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)